What is Arcadia Bioscien's earnings per share (EPS)?

Arcadia Bioscien (RKDA) reported diluted earnings per share of $-1.71 for fiscal year 2025. This represents a 66.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Arcadia Bioscien Financials

RKDA

Source SEC Filings (10-K/10-Q) Updated Mar 26, 2026 Currency USD FYE March

This page shows Arcadia Bioscien (RKDA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 29/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Arcadia Bioscien has an operating margin of -51.5%, meaning the company retains $-51 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -72.3% the prior year.

Growth

Arcadia Bioscien's revenue declined 3.7% year-over-year, from $5.0M to $4.9M. This contraction results in a growth score of 27/100.

Leverage

Arcadia Bioscien carries a low D/E ratio of 0.58, meaning only $0.58 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Arcadia Bioscien's current ratio of 3.09 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Arcadia Bioscien generated -$4.7M in operating cash flow, capex of $16K consumed most of it, leaving -$4.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Arcadia Bioscien generates a -56.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -113.1% the prior year.

Piotroski F-Score Weak

2/9

Arcadia Bioscien passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

2.03x

For every $1 of reported earnings, Arcadia Bioscien generates $2.03 in operating cash flow (-$4.7M OCF vs -$2.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-11.3x

Arcadia Bioscien earns $-11.3 in operating income for every $1 of interest expense (-$2.5M vs $221K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.9M

YoY-3.7%

5Y CAGR-9.6%

10Y CAGR-1.1%

Arcadia Bioscien generated $4.9M in revenue in fiscal year 2025. This represents a decrease of 3.7% from the prior year.

EBITDA

-$2.5M

YoY+31.3%

Arcadia Bioscien's EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.3% from the prior year.

Net Income

-$2.3M

YoY+66.8%

Arcadia Bioscien reported -$2.3M in net income in fiscal year 2025. This represents an increase of 66.8% from the prior year.

EPS (Diluted)

$-1.71

YoY+66.9%

Arcadia Bioscien earned $-1.71 per diluted share (EPS) in fiscal year 2025. This represents an increase of 66.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$4.8M

YoY+50.6%

Arcadia Bioscien generated -$4.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 50.6% from the prior year.

Cash & Debt

$259K

YoY-93.9%

5Y CAGR-55.0%

10Y CAGR-36.4%

Arcadia Bioscien held $259K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+50.7%

Arcadia Bioscien had 2M shares outstanding in fiscal year 2025. This represents an increase of 50.7% from the prior year.

Margins & Returns

Gross Margin

36.2%

YoY-5.0pp

5Y CAGR+0.9pp

10Y CAGR-47.3pp

Arcadia Bioscien's gross margin was 36.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 5.0 percentage points from the prior year.

Operating Margin

-51.5%

YoY+20.9pp

5Y CAGR+107.6pp

10Y CAGR+236.0pp

Arcadia Bioscien's operating margin was -51.5% in fiscal year 2025, reflecting core business profitability. This is up 20.9 percentage points from the prior year.

Net Margin

-48.1%

YoY+91.3pp

5Y CAGR+9.8pp

10Y CAGR+283.5pp

Arcadia Bioscien's net profit margin was -48.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 91.3 percentage points from the prior year.

Return on Equity

-56.5%

YoY+56.6pp

5Y CAGR-39.7pp

10Y CAGR-11.9pp

Arcadia Bioscien's ROE was -56.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 56.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$9K

YoY-83.0%

5Y CAGR-74.3%

10Y CAGR-49.9%

Arcadia Bioscien invested $9K in research and development in fiscal year 2025. This represents a decrease of 83.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$16K

YoY+0.0%

5Y CAGR-63.1%

10Y CAGR-20.1%

Arcadia Bioscien invested $16K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

RKDA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$4.9M-3.7%	$5.0M+13.3%	$4.5M-40.0%	$7.4M+9.4%	$6.8M-15.6%	$8.0M
Cost of Revenue	$3.1M+4.6%	$3.0M+36.3%	$2.2M-64.4%	$6.1M-29.9%	$8.7M+67.5%	$5.2M
Gross Profit	$1.8M-15.5%	$2.1M-8.7%	$2.3M+73.1%	$1.3M+168.3%	-$1.9M-168.0%	$2.8M
R&D Expenses	$9K-83.0%	$53K-17.2%	$64K-95.8%	$1.5M-61.2%	$3.9M-51.1%	$8.0M
SG&A Expenses	$7.0M-27.4%	$9.6M+17.1%	$8.2M-45.2%	$15.0M-34.4%	$22.9M+39.3%	$16.5M
Operating Income	-$2.5M+31.5%	-$3.6M+40.2%	-$6.1M+56.4%	-$14.0M+60.6%	-$35.5M-178.0%	-$12.8M
Interest Expense	$221K-71.7%	$782K+12.5%	$695K+140.5%	$289K+1345.0%	$20K-57.4%	$47K
Income Tax	$8K0.0%	$8K0.0%	$8K-42.9%	$14K+600.0%	$2K+101.6%	-$124K
Net Income	-$2.3M+66.8%	-$7.0M+49.7%	-$14.0M+9.1%	-$15.4M-4.9%	-$14.7M-214.9%	-$4.7M
EPS (Diluted)	$-1.71+66.9%	$-5.17+54.2%	$-11.29+56.0%	$-25.65+6.9%	$-27.56	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$1.3M-10.5%	$1.5M+21.3%	$1.2M-1.2%	$1.2M-20.9%	$1.5M+17.7%	$1.3M+32.3%	$987K+57.4%	$627K
Cost of Revenue	$884K+7.3%	$824K+20.8%	$682K-17.5%	$827K-19.9%	$1.0M+63.0%	$633K+34.4%	$471K+2516.7%	$18K
Gross Profit	$418K-33.8%	$631K+21.8%	$518K+33.5%	$388K-23.2%	$505K-25.0%	$673K+30.4%	$516K-15.3%	$609K
R&D Expenses	$0-100.0%	$9K	$0-100.0%	$13K-45.8%	$24K+140.0%	$10K+66.7%	$6K+101.8%	-$337K
SG&A Expenses	$1.6M-26.0%	$2.1M+22.2%	$1.7M-34.5%	$2.7M+18.5%	$2.2M-16.5%	$2.7M+30.1%	$2.1M+808.4%	$227K
Operating Income	-$1.2M-129.9%	-$501K-194.5%	$530K+123.2%	-$2.3M-29.5%	-$1.8M-188.9%	$2.0M+224.7%	-$1.6M-357.8%	$616K
Interest Expense	$7K-22.2%	$9K-95.7%	$207K-41.5%	$354K+51.9%	$233K+55.3%	$150K+233.3%	$45K-71.3%	$157K
Income Tax	N/A	N/A	N/A	N/A	$0	$0	N/A	N/A
Net Income	$856K+119.2%	-$4.5M-271.5%	$2.6M+164.0%	-$4.1M-152.1%	-$1.6M-251.9%	$1.1M+143.8%	-$2.4M+15.1%	-$2.9M
EPS (Diluted)	$0.62+119.0%	$-3.26-271.6%	$1.90	N/A	$-1.18-251.3%	$0.78+143.8%	$-1.78	N/A

RKDA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$6.5M-51.6%	$13.5M-31.4%	$19.7M-31.9%	$28.9M-34.1%	$43.9M-7.2%	$47.3M
Current Assets	$6.4M-31.2%	$9.2M-38.3%	$15.0M-41.1%	$25.4M-28.2%	$35.4M+11.6%	$31.7M
Cash & Equivalents	$259K-93.9%	$4.2M-34.9%	$6.5M-68.4%	$20.6M-28.0%	$28.7M+104.3%	$14.0M
Inventory	$1.2M+34.1%	$904K+8.0%	$837K-63.9%	$2.3M-47.6%	$4.4M+16.3%	$3.8M
Accounts Receivable	N/A	N/A	N/A	N/A	$1.4M-2.6%	$1.4M
Goodwill	N/A	N/A	N/A	N/A	N/A	$408K
Total Liabilities	$2.4M-67.0%	$7.3M+4.2%	$7.0M-12.7%	$8.0M-36.9%	$12.7M-32.3%	$18.8M
Current Liabilities	$2.1M-19.7%	$2.6M-28.6%	$3.6M-14.7%	$4.2M-16.5%	$5.0M-20.2%	$6.3M
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$2.1M
Total Equity	$4.1M-33.5%	$6.2M-51.5%	$12.8M-38.9%	$21.0M-32.4%	$31.1M+12.1%	$27.7M
Retained Earnings	-$281.2M-0.8%	-$278.9M-2.6%	-$271.8M-5.4%	-$257.9M-13.9%	-$226.5M-6.9%	-$211.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$8.6M+10.2%	$7.8M-40.0%	$13.0M-3.9%	$13.5M-11.3%	$15.2M-12.3%	$17.4M+8.2%	$16.0M-18.6%	$19.7M
Current Assets	$8.4M+10.7%	$7.6M-14.3%	$8.8M-4.3%	$9.2M-13.7%	$10.7M-13.9%	$12.4M+6.8%	$11.6M-22.2%	$15.0M
Cash & Equivalents	$1.1M-18.6%	$1.4M-56.4%	$3.2M-25.5%	$4.2M+7.8%	$3.9M-28.5%	$5.5M+65.9%	$3.3M-49.1%	$6.5M
Inventory	$1.5M-2.1%	$1.5M+15.9%	$1.3M+42.1%	$904K+8.3%	$835K-14.6%	$978K-46.6%	$1.8M+118.8%	$837K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.1M-3.5%	$3.3M-20.3%	$4.1M-44.0%	$7.3M+43.2%	$5.1M-12.3%	$5.8M+4.3%	$5.6M-20.6%	$7.0M
Current Liabilities	$2.3M+24.3%	$1.8M-17.0%	$2.2M-13.5%	$2.6M+10.1%	$2.3M-13.7%	$2.7M-6.3%	$2.9M-19.8%	$3.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.4M+20.1%	$4.5M-49.1%	$8.9M+43.1%	$6.2M-39.5%	$10.3M-12.1%	$11.7M+10.2%	$10.6M-17.3%	$12.8M
Retained Earnings	-$279.9M+0.3%	-$280.7M-1.6%	-$276.3M+0.9%	-$278.9M-1.5%	-$274.8M-0.6%	-$273.2M+0.4%	-$274.3M-0.9%	-$271.8M

RKDA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$4.7M+50.6%	-$9.6M+37.2%	-$15.3M-9.4%	-$14.0M+46.0%	-$25.9M+14.4%	-$30.2M
Capital Expenditures	$16K0.0%	$16K+220.0%	$5K-93.1%	$72K-92.9%	$1.0M-56.9%	$2.3M
Free Cash Flow	-$4.8M+50.6%	-$9.6M+37.1%	-$15.3M-8.9%	-$14.0M+47.7%	-$26.9M+17.4%	-$32.6M
Investing Cash Flow	$750K-89.8%	$7.3M+269.0%	-$4.3M-406.6%	$1.4M-91.5%	$16.6M-3.9%	$17.3M
Financing Cash Flow	$6K-33.3%	$9K-99.8%	$5.5M+22.0%	$4.5M-79.4%	$21.9M+6.5%	$20.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$257K+87.4%	-$2.0M-28.0%	-$1.6M+27.2%	-$2.2M-24.5%	-$1.8M+28.7%	-$2.5M+23.5%	-$3.2M+22.6%	-$4.1M
Capital Expenditures	$0	$0	$0	$0	$0-100.0%	$3K-76.9%	$13K	$0
Free Cash Flow	-$257K+87.4%	-$2.0M-28.0%	-$1.6M+27.2%	-$2.2M-24.5%	-$1.8M+28.8%	-$2.5M+23.7%	-$3.2M+22.2%	-$4.1M
Investing Cash Flow	$0-100.0%	$250K-50.0%	$500K-80.1%	$2.5M+1297.2%	$180K-96.1%	$4.6M+115975.0%	$4K-92.3%	$52K
Financing Cash Flow	$1K	$0-100.0%	$5K	$0-100.0%	$4K	$0-100.0%	$5K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RKDA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	36.2%-5.0pp	41.3%-9.9pp	51.2%+33.4pp	17.8%+46.2pp	-28.4%-63.7pp	35.3%
Operating Margin	-51.5%+20.9pp	-72.3%+64.7pp	-137.0%+51.8pp	-188.8%+335.2pp	-524.0%-364.9pp	-159.1%
Net Margin	-48.1%+91.3pp	-139.5%+174.4pp	-313.9%-106.6pp	-207.3%+8.9pp	-216.2%-158.3pp	-57.9%
Return on Equity	-56.5%+56.6pp	-113.1%-4.2pp	-108.9%-35.8pp	-73.1%-25.9pp	-47.1%-30.4pp	-16.8%
Return on Assets	-35.7%+16.3pp	-52.1%+18.9pp	-71.0%-17.8pp	-53.2%-19.8pp	-33.4%-23.5pp	-9.8%
Current Ratio	3.09-0.5	3.61-0.6	4.17-1.9	6.03-1.0	7.02+2.0	5.02
Debt-to-Equity	0.58-0.6	1.17+0.6	0.55+0.2	0.38+0.4	0.00-0.1	0.08
FCF Margin	-97.9%+92.7pp	-190.6%+152.9pp	-343.5%-154.1pp	-189.4%+207.0pp	-396.4%+8.8pp	-405.2%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	32.1%-11.3pp	43.4%+0.2pp	43.2%+11.2pp	31.9%-0.9pp	32.9%-18.7pp	51.5%-0.8pp	52.3%-44.9pp	97.1%
Operating Margin	-88.5%-54.0pp	-34.4%-78.6pp	44.2%+231.8pp	-187.7%-73.1pp	-114.5%-266.1pp	151.6%+312.5pp	-160.9%-259.1pp	98.3%
Net Margin	65.8%+372.1pp	-306.4%-523.0pp	216.6%+551.1pp	-334.5%-229.6pp	-104.9%-186.1pp	81.2%+326.7pp	-245.5%+209.5pp	-455.0%
Return on Equity	15.7%+114.1pp	-98.4%-127.5pp	29.2%+94.5pp	-65.3%-49.6pp	-15.7%-24.7pp	9.1%+31.9pp	-22.8%-0.6pp	-22.2%
Return on Assets	10.0%+67.2pp	-57.2%-77.3pp	20.0%+50.1pp	-30.1%-19.5pp	-10.6%-16.7pp	6.1%+21.2pp	-15.1%-0.6pp	-14.5%
Current Ratio	3.67-0.5	4.12+0.1	3.99+0.4	3.61-1.0	4.600.0	4.61+0.6	4.05-0.1	4.17
Debt-to-Equity	0.58-0.1	0.72+0.3	0.46-0.7	1.17+0.7	0.490.0	0.50-0.0	0.52-0.0	0.55
FCF Margin	-19.7%+120.0pp	-139.7%-7.4pp	-132.3%+47.3pp	-179.6%-65.6pp	-114.0%+74.3pp	-188.3%+138.3pp	-326.6%+334.5pp	-661.1%

Similar Companies

Healthy Choice Wellness Corp HCWC

$5.5M

Farmmi Inc FAMI

$16.6M

Naturl Alt Intl NAII

$16.6M

Australian Oilseeds COOT

$17.2M

STEAKHOLDER FOODS LTD STKH

$2.2M

Frequently Asked Questions

What is Arcadia Bioscien's annual revenue?

Arcadia Bioscien (RKDA) reported $4.9M in total revenue for fiscal year 2025. This represents a -3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Arcadia Bioscien's revenue growing?

Arcadia Bioscien (RKDA) revenue declined by 3.7% year-over-year, from $5.0M to $4.9M in fiscal year 2025.

Is Arcadia Bioscien profitable?

No, Arcadia Bioscien (RKDA) reported a net income of -$2.3M in fiscal year 2025, with a net profit margin of -48.1%.

What is Arcadia Bioscien's EBITDA?

Arcadia Bioscien (RKDA) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Arcadia Bioscien's gross margin?

Arcadia Bioscien (RKDA) had a gross margin of 36.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Arcadia Bioscien's operating margin?

Arcadia Bioscien (RKDA) had an operating margin of -51.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Arcadia Bioscien's net profit margin?

Arcadia Bioscien (RKDA) had a net profit margin of -48.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Arcadia Bioscien's return on equity (ROE)?

Arcadia Bioscien (RKDA) has a return on equity of -56.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Arcadia Bioscien's free cash flow?

Arcadia Bioscien (RKDA) generated -$4.8M in free cash flow during fiscal year 2025. This represents a 50.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Arcadia Bioscien's operating cash flow?

Arcadia Bioscien (RKDA) generated -$4.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Arcadia Bioscien's total assets?

Arcadia Bioscien (RKDA) had $6.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Arcadia Bioscien's capital expenditures?

Arcadia Bioscien (RKDA) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Arcadia Bioscien spend on research and development?

Arcadia Bioscien (RKDA) invested $9K in research and development during fiscal year 2025.

How many shares does Arcadia Bioscien have outstanding?

Arcadia Bioscien (RKDA) had 2M shares outstanding as of fiscal year 2025.

What is Arcadia Bioscien's current ratio?

Arcadia Bioscien (RKDA) had a current ratio of 3.09 as of fiscal year 2025, which is generally considered healthy.

What is Arcadia Bioscien's debt-to-equity ratio?

Arcadia Bioscien (RKDA) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Arcadia Bioscien's return on assets (ROA)?

Arcadia Bioscien (RKDA) had a return on assets of -35.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Arcadia Bioscien's cash runway?

Based on fiscal year 2025 data, Arcadia Bioscien (RKDA) had $259K in cash against an annual operating cash burn of $4.7M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Arcadia Bioscien's Piotroski F-Score?

Arcadia Bioscien (RKDA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Arcadia Bioscien's earnings high quality?

Arcadia Bioscien (RKDA) has an earnings quality ratio of 2.03x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Arcadia Bioscien cover its interest payments?

Arcadia Bioscien (RKDA) has an interest coverage ratio of -11.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Arcadia Bioscien?

Arcadia Bioscien (RKDA) scores 29 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.